Skip to content

Internuclear Ophthalmoplegia and Multiple Sclerosis: a Multicenter Retrospective Study

Internuclear Ophthalmoplegia and Multiple Sclerosis: a Multicenter Retrospective Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07560995
Acronym
INO&MS
Enrollment
200
Registered
2026-05-01
Start date
2026-05-01
Completion date
2027-05-01
Last updated
2026-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Internuclear Ophthalmoplegia, Multiple Sclerosis

Brief summary

Internuclear ophthalmoplegia is a symptom frequently associated with multiple sclerosis (MS), although other etiologies are possible. Some patients do not meet the diagnostic criteria for MS at the time of the internuclear ophthalmoplegia episode but subsequently convert to MS. Studying this specific clinical situation may help enable earlier diagnosis of MS. The objective is to analyze the proportion of patients with isolated internuclear ophthalmoplegia who convert to multiple sclerosis and to identify factors associated with this conversion. The study hypothesis is that the presence of internuclear ophthalmoplegia is highly suggestive of multiple sclerosis, particularly when cerebrospinal fluid-specific oligoclonal bands are present.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with internuclear ophthalmoplegia listed as a primary or associated diagnosis * Patients hospitalized in a neurology department

Exclusion criteria

\- Patients under 18 years of age

Design outcomes

Primary

MeasureTime frameDescription
Analyze the proportion of patients with isolated internuclear ophthalmoplegia who convert to multiple sclerosis.1 yearProportion of patients with isolated internuclear ophthalmoplegia who converted to multiple sclerosis during follow-up.

Countries

France

Contacts

CONTACTKévin BIGAUT
kevin.bigaut@chru-strasbourg.fr+33 3 88 12 60 96
CONTACTSebille COLIN
sebille.colin@chru-strasbourg.fr+33 3 88 11 52 17
PRINCIPAL_INVESTIGATORKévin BIGAUT

Hôpitaux Universitaires de Strasbourg

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 9, 2026